enzh-TWfrdeitjaptrues

Your privacy is important to us, so we operate the site by the following principles:

Confidentiality
You may use our site without disclosing personally identifiable information. We want to be clear that we will not obtain such information about you unless you choose to submit it to us. If you supply personally identifiable information (such as name, address or telephone numbers) for various purposes on this site, we only use the information for that purpose (such as to provide the service or information you have requested).

Security
The Dana-Farber Waldenstrom's Macroglobulinemia Program takes every precaution to protect our users' information. When a registration/order form asks users to enter sensitive information (such as credit card number and/or diagnosis), that information is encrypted and is protected with the best encryption software in the industry- SSL.

Should you electronically request a referral to a Dana-Farber physician, we will use the information you submit to arrange for care where appropriate. While we use SSL encryption to protect sensitive information online, we also do everything in our power to protect user-information off line. Our software and hardware is configured to provide maximum security.

To use our contact form, the Magic Word is Bing.

Cookies
The Dana-Farber Waldenstrom's Macroglobulinemia Program Web sites use cookies to track traffic coming to our site. We do not collect personal data such as name, age, phone number, e-mail, or mailing address. Cookies will also be used to identify a person who chooses to register on our site. If you choose to register on our site and are given a password for an event, give donations on line, or choose to enroll in our e-mail subscription services, we will identify you with cookies. You will always have a chance to opt out at any time.

Information Collection and Use
The Dana-Farber Waldenstrom's Macroglobulinemia Program is the sole owner of the personal medical information collected on this site. We will not sell, share, or rent this information to others. The Dana-Farber occasionally trades its contributor mailing lists with other non-profit organizations. This process saves us money and is carefully monitored and one may always opt-out.

Donations on the Web
When you make a gift on our site, your e-mail will be entered into our donor database. We may send you e-mails or mailings in the future informing you of other giving opportunities or providing news about The Dana-Farber Bing Center for Waldenstrom's Macroglobulinemia. If you choose not to receive any further communication from us, you may opt-out by e-mailing This email address is being protected from spambots. You need JavaScript enabled to view it. or calling our offices at 1-617-632-6285.

Latest Bing Center News

Great Debates in Hematological Malignancies - 2021

Great Debates in Hematological Malignancies - 2021

We're pleased to announce that registration is now open for the 2021 Great Debates & Updates Conferences. Each meeting will cover the most critical updates occurring in the field, while incorporating a distinct focus on the latest advances and treatment options.

Read more..

A WMer's thoughts around the holidays from her to you....

A WMer's thoughts around the holidays from her to you....

Thanksgiving 2020: Home, but not Alone: Has your sense of time shifted lately?  Does avoiding people feel bizarre, and has Purell become your new best friend?  Do you spot beauty in surprising places, and feel the rhythm of your breath inside your mask?

Read more..

Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia

Genomic and Treatment Advances in Waldenstrom's Macroglobulinemia

On October 21, 2020, Dr. Steven Treon gave a webcast lecture to the Canadian National WMFC Patient Support Group. The main topic was genomic & treatment advances in WM, with the discussion also including the related issues surrounding COVID-19.

Read more..

Treatment Advancements are Improving Survivorship and Prompting Hope

Treatment Advancements are Improving Survivorship and Prompting Hope

Is a cure for Waldenstrom macroglobulinemia on the horizon? In the past several decades Waldenstrom’s survivorship has vastly improved due to safer and more effective treatment drugs. Could this indicate that a cure might be within reach? Patient Power Co-Founder Andrew Schorr speaks with Dr. Steven Treon, director, Bing Center for Waldenstrom Macroglobulinemia, Dana-Farber Cancer Institute, about his predictions for the future of Waldenstrom macroglobulinemia treatment.

Read more..

IMS Virtual Workshop November 6-7, 2020

IMS Virtual Workshop November 6-7, 2020

Dr. Steven Treon will be giving a lecture on "New Insights into Waldenstrom's in Session 4 of this virtual Workshop. If you are interested in attending, registration will be closing soon.

Read more..

Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020

Bing-Neel Support Group/Ask the Doctor meeting: Nov 22, 2020

The Eastern Massachusetts IWMF Support Group invites WM/Bing-Neel patients and caregivers from across the globe to join us in the first-ever support group meeting focused on this particularly rare WM complication. With Bing-Neel specialists, Dr. Steve Treon and Dr. Jorge Castillo of Dana-Farber Cancer Institute.

Read more..

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Consensus treatment recommendations from the tenth International Workshop for Waldenström Macroglobulinaemia

Every two years WM experts from around the world meet to discuss the latest research and developments. The last meeting, IWWM-10 was held in New York in October, 2018, and the consensus recommendations on treatment have just been published in The Lancet. Registration (to read the article) is free.

Read more..

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib Demonstrates Long-Term Safety, Activity in Relapsed/Refractory WM

Ibrutinib is a highly active and tolerable therapy for symptomatic, relapsed, or refractory patients with Waldenström macroglobulinemia (WM) and a preferable option for use in previously treated patients, according to a study published in the Journal of Clinical Oncology (2020;JCO2000555. doi:10.1200/JCO.20.00555).

Read more..

The fourth issue of the 21st volume of the IWMF Torch is now online!

The fourth issue of the 21st volume of the IWMF Torch is now online!

If you’ve ever had questions about clinical trials, this issue will help clarify various aspects of them, from both the doctor’s and the patient’s perspectives. It will be obvious that medical as well as personal reasons need to be considered before making the plunge.

Read more..

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK Inhibitors Transform Waldenström Macroglobulinemia Management

BTK inhibitors have transformed the treatment of patients with Waldenström macroglobulinemi; with 4 agents under examination in the space, selection will depend on availability, toxicity, convenience, and cost.

Read more..